AN aHUS PATIENT’S TREATMENT DISCONTINUATION MODEL
Without any further comment here is the model mentioned in the previous article ( which if you have not already seen can be read HERE ). Have a go at…
Without any further comment here is the model mentioned in the previous article ( which if you have not already seen can be read HERE ). Have a go at…
As sometimes happens in life, things can arise as a group that makes people take a bit more notice than if they’d had singular appearances. In medical circles, it’s not…
Last year Global Action brought attention to a research article ( Closing the CaHUS knowledge gap ) which stood out as one of the best contributions to aHUS knowledge we…
Atypical HUS – research updates for Feb 2024
Pregnancy is a common trigger of aHUS, this can impact on someone who is predisposed or related to someone predisposed to aHUS and had had aHUS and so it is…
The United States Thrombotic Microangiopathy (USTMA) Consortium was formed in 2014 as a collaborative initiative to organize research efforts in the thrombotic microangiopathies (TMAs). Atypical HUS is often known as…
Stopping aHUS treatment when no longer needed is a big decision for patients. Global Action put the patients research agenda question to our expert. Can a complement inhibitor be stopped…
Genetic testing again a topic but this time it is of the patient; and is important for prognosis as well as diagnosis of the patients. However some healthcare providers are…